This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 May;180(5):977-978.

doi: 10.1111/bjd.17784.

Safety of long-term interleukin-23 inhibition in patients with psoriasis

E B Lee¹, J J Wu²

Affiliations

Affiliations

¹ University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, U.S.A.
² Dermatology Research and Education Foundation, Irvine, CA, U.S.A.

PMID: 31025743
DOI: 10.1111/bjd.17784

Comment

Safety of long-term interleukin-23 inhibition in patients with psoriasis

E B Lee et al. Br J Dermatol. 2019 May.

. 2019 May;180(5):977-978.

doi: 10.1111/bjd.17784.

Authors

E B Lee¹, J J Wu²

Affiliations

¹ University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, U.S.A.
² Dermatology Research and Education Foundation, Irvine, CA, U.S.A.

PMID: 31025743
DOI: 10.1111/bjd.17784

No abstract available

PubMed Disclaimer

Comment on

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB. Reich K, et al. Br J Dermatol. 2019 May;180(5):1039-1049. doi: 10.1111/bjd.17454. Br J Dermatol. 2019. PMID: 30485400 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information